U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H29NO3
Molecular Weight 307.4278
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BETAXOLOL

SMILES

CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1

InChI

InChIKey=NWIUTZDMDHAVTP-UHFFFAOYSA-N
InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C18H29NO3
Molecular Weight 307.4278
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Betaxolol or SL 75212, (± )-1-(isopropylamino)-3-(p-(cyclopropylmethoxyethyl-phenoxy)2-propranol, is a potent cardioselective beta1-adrenoceptor antagonist devoid of intrinsic sympathomimetic activity with very weak local anaesthetic properties. Oral betaxolol has been used for the treatment of essential hypertension. Betaxolol is used topically in glaucoma and ocular hypertension.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
32.0 nM [Ki]
236.0 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BETOPTIC
Primary
BETOPTIC
Primary
KERLONE

Cmax

ValueDoseCo-administeredAnalytePopulation
89.8 ng/mL
40 mg single, oral
BETAXOLOL blood
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
2096 μg × h/L
40 mg single, oral
BETAXOLOL blood
Homo sapiens
610 μg × h/L
10 mg single, intravenous
BETAXOLOL blood
Homo sapiens
971.11 ng × h/mL
20 mg single, oral
BETAXOLOL plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
12.3 h
20 mg single, oral
BETAXOLOL plasma
Homo sapiens

Doses

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

PubMed

Sample Use Guides

In Vivo Use Guide
The initial dose of Kerlone (betaxolol hydrochloride tablets) in hypertension is ordinarily 10 mg once daily either alone or added to diuretic therapy. The full antihypertensive effect is usually seen within 7 to 14 days. If the desired response is not achieved the dose can be doubled after 7 to 14 days. Increasing the dose beyond 20 mg has not been shown to produce a statistically significant additional antihypertensive effect; but the 40-mg dose has been studied and is well tolerated. An increased effect (reduction) on heart rate should be anticipated with increasing dosage. If monotherapy with Kerlone does not produce the desired response, the addition of a diuretic agent or other antihypertensive should be considered. The usual dose is one drop of BETOPTIC® (betaxolol hydrochloride) Eye Drops 0.5% or BETOPTIC S Eye Drops 0.25% in the affected eye(s) twice daily. In some patients, the intraocular pressure lowering response to BETOPTIC Eye Drops 0.5% or BETOPTIC S Eye Drops 0.25% may require a few weeks to stabilise. Clinical follow up should include a determination of the intraocular pressure during the first month of treatment with BETOPTIC Eye Drops 0.5% or BETOPTIC S Eye Drops 0.25%. Thereafter, intraocular pressure should be determined on an individual basis at the judgement of the physician.
Route of Administration: Other
In Vitro Use Guide
Betaxolol (162 microM, 16.2 microM, and 1.62 microM) induced a significant increase in [Ca2+]i in cultured corneal endothelial cells
Substance Class Chemical
Record UNII
O0ZR1R6RZ2
Record Status Validated (UNII)
Record Version